Anti-Mouse CD19 Monoclonal Antibodies

PA007363.r2a: In vivo Grade Recombinant Anti-mouse CD19 Monoclonal Antibody, Rat IgG2a Kappa (Clone: 1D3)

Recombinant rat IgG2a Monoclonal Antibody. 
Clone: 1D3.
Isotype: Rat IgG2a kappa.
Source: The anti-mouse CD19 monoclonal antibody (clone: 1D3) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 1D3) specifically binds to the mouse CD19 protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD19 protein. 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

The 1D3 antibody binds to the mouse CD19 protein, a transmembrane protein expressed in all B lineage cells including mouse plasma cells. CD19 plays two major roles in mouse B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.

References of Anti-mouse CD19 Monoclonal Antibody:

Transcription Factor Repertoire of Homeostatic Eosinophilopoiesis.
Bouffi, C., et al. J Immunol. 2015 Sep 15;195(6):2683-95. doi: 10.4049/jimmunol.1500510. PMID: 26268651
The production of mature eosinophils (Eos) is a tightly orchestrated process with the aim to sustain normal Eos levels in tissues while also maintaining low numbers of these complex and sensitive cells in the blood. ...Our analyses revealed a markedly greater number of transcriptome alterations associated with Eos maturation (1199 genes) than with Eos-lineage commitment (490 genes), highlighting the greater transcriptional investment necessary for differentiation. ...Our analyses also delineated a 976-gene Eos-lineage transcriptome that included a repertoire of 56 transcription factors, many of which have never previously been associated with Eos. ...Epigenetic studies revealed a distinct distribution of active chromatin marks between genes induced with lineage commitment and genes induced with cell maturation during Eos development. ...In addition, Aiolos and Helios binding sites were significantly enriched in genes expressed by EoPs and Eos with active chromatin, highlighting a potential novel role for Helios and Aiolos in regulating gene expression during Eos development.
Tags: anti-mouse CD19 1D3 antibody; anti-mouse CD19 1D3

Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
Dai, M., et al. Clin Cancer Res. 2015 Mar 1;21(5):1127-38. doi: 10.1158/1078-0432.CCR-14-1339. PMID: 25142145
More than 50% of tumor-bearing mice had complete regression and long-term survival after tumor injection with mAbs recognizing CD137/PD-1/CTLA-4/CD19 with similar responses in three models. ...There were few side effects, and therapy-resistant tumors were not observed. Transplanted tumor cells rapidly caused a Th2 response with increased CD19 cells. ...Successful therapy shifted this response to the Th1 phenotype with decreased CD19 cells and increased numbers of long-term memory CD8 effector cells and T cells making IFNγ and TNFα. ...Intratumoral injection of mAbs recognizing CD137/PD-1/CTLA-4/CD19 can eradicate established tumors and reverse a Th2 response with tumor-associated CD19 cells to Th1 immunity, whereas a combination lacking anti-CD19 is less effective. ...Regression was always associated with a strong Th1-type response in tumor, tumor-draining lymph nodes, and spleen and was accompanied by severe reduction of the number of CD19 cells in tumors and draining lymph nodes.
Tags: anti-mouse CD19 1D3 in vivo; anti-mouse CD19 1D3 mAb in vivo

Collaborative interactions between type 2 innate lymphoid cells and antigen-specific CD4+ Th2 cells exacerbate murine allergic airway diseases with prominent eosinophilia.
Liu, B., et al. J Immunol. 2015 Apr 15;194(8):3583-93. doi: 10.4049/jimmunol.1400951. PMID: 25780046
Type-2 innate lymphoid cells (ILC2s) and the acquired CD4+ Th2 and Th17 cells contribute to the pathogenesis of experimental asthma; however, their roles in Ag-driven exacerbation of chronic murine allergic airway diseases remain elusive. ...In this study, we report that repeated intranasal rechallenges with only OVA Ag were sufficient to trigger airway hyperresponsiveness, prominent eosinophilic inflammation, and significantly increased serum OVA-specific IgG1 and IgE in rested mice that previously developed murine allergic airway diseases. ...The recall response to repeated OVA inoculation preferentially triggered a further increase of lung OVA-specific CD4+ Th2 cells, whereas CD4+ Th17 and ILC2 cell numbers remained constant. ...Furthermore, the acquired CD4+ Th17 cells in Stat6−/−/IL-17–GFP mice, or innate ILC2s in CD4+ T cell–ablated mice, failed to mount an allergic recall response to OVA Ag. ...In return, ILC2s enhanced Ag-mediated proliferation of cocultured CD4+ Th2 cells and their cytokine production, and promoted eosinophilic airway inflammation and goblet cell hyperplasia driven by adoptively transferred Ag-specific CD4+ Th2 cells.
Tags: anti-mouse CD19 1D3 antibody in animal model; anti-mouse CD19 1D3 mAb in animal model

ADAM17 limits the expression of CSF1R on murine hematopoietic progenitors.
Becker, A. M., et al. Exp Hematol. 2015 Jan;43(1):44-52.e1-3. doi: 10.1016/j.exphem.2014.10.001. PMID: 25308957
Hematopoietic stem cells traverse through a series of developmental intermediates, termed progenitors, en route to lineage commitment and maturation. ...As differentiation progresses, these progenitors lose their ability to undergo self-renewing divisions. ...At each of these branches, these progenitors are considered to be committed to the remaining blood lineages that they can still generate. ...As highlighted by this disagreement, the mechanisms by which lymphoid progenitors limit myeloid output in vivo remain incompletely understood. ...Another non–mutually exclusive possibility is that ALPs reduce the expression of myeloid cytokine receptors such that they are unresponsive to the in vivo concentrations of such factors. Yet by providing excess amounts of myeloid lineage-promoting cytokines in vitro, lymphoid progenitors can still generate macrophages and neutrophils. Indeed, ectopic expression of certain cytokine receptors allows for robust myeloid cell production by lymphoid progenitors.
Tags: anti-mouse CD19 1D3 in cancer research; anti-mouse CD19 1D3 antibody in cancer research

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.
Carmi, Y., et al. Nature. 2015 May 7;521(7550):99-104. doi: 10.1038/nature14424. PMID: 25924063
Right graph shows MFI of the binding of 2 μg of each IgG to 1 × 105 B16 cells. c, Serum levels of IgG (left) and IgM (right) in C57BL/6 and 129S1 mice following i.p injection with anti-B220 and anti-CD19 antibodies (n = 8, 3 independent experiments). ...Representative flow cytometric analysis and confocal images from one out of three independent experiments of B16-derived DCs cultured overnight with CFSE-labelled fixed B16 cells (n = 8, 10 independent experiments). Shown are the mean values ± s.e.m. *P < 0.05; **P < 0.01. ...Also shown is the lack of B16 tumour growth in C57BL/6 mice that were re-challenged with 2 × 105 B16 tumour cells following the regression of this tumour after treatment with allogeneic IgG + TNFα + anti-CD40 (n = 8, 2 independent experiments). ...Lower left: B16 growth in C57BL/6 mice treated with TNFα + anti-CD40 + allogeneic IgG and injected with rat IgG, with rat anti-CD4, or with rat-CD8. ...Gate shown: CD8+ T cells (n = 10, 3 independent experiments).
Tags: anti-mouse CD19 1D3 mAb in cancer research; anti-mouse CD19 1D3 antibody in mouse tumor model

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.
Dai, M., et al. J Immunother. 2013 May;36(4):248-57. doi: 10.1097/CJI.0b013e3182943549. PMID: 23603859
Mice with intraperitoneal ID8 ovarian carcinoma or subcutaneous SW1 melanoma were injected with monoclonal antibodies (mAbs) to CD137+PD-1+CTLA4 7–15 days after tumor initiation. ...Survival of mice with ID8 tumors tripled and >40% of mice with SW1 tumors remained healthy >150 days after last treatment and are probably cured. ...Therapeutic efficacy was associated with a systemic immune response with memory and antigen specificity, required CD4+ cells and involved CD8+ cells and NK cells to a less extent. ...The 3 mAb combination significantly decreased CD19+ cells at tumor sites, increased IFN-γ and TNF-α producing CD4+ and CD8+ T cells and mature CD86+ dendritic cells (DC), and it increased the ratios of effector CD4+ and CD8+ T cells to CD4+Foxp3+ regulatory T (Treg) cells and to CD11b+Gr-1+ myeloid suppressor cells (MDSC). ...Data from ongoing experiments show that intratumoral injection of a combination of mAbs to CD137+PD-1+CTLA4+CD19 can induce complete regression and dramatically prolong survival also in the TC1 carcinoma and B16 melanoma models, suggesting that the approach has general validity.
Tags: function of anti-mouse CD19 1D3; function of anti-mouse CD19 1D3 antibody

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo, Z., et al. J Transl Med. 2013 Sep 17;11:215. doi: 10.1186/1479-5876-11-215. PMID: 24044888
Therapeutic anti-CD137 (Clone lob12.3; Catalog#BE0169), anti-TIM-3 (Clone RMT3-23; Catalog#BE0115), anti-CD4 (Clone GK1.5; Catalog#:BE0003-1), anti-CD8 (Clone 2.43; Catalog#:BE0061), anti-NK1.1 (Clone PK136; Catalog#:BE0036), anti-CD19 (Clone 1D3; Catalog#:BE0150) and control (Clone 2A3; Catalog#:BE0089) were purchased from BioXcell (West Lebanon, NH). ...For depletion of immune cells, mice were injected i.p. with 500 μg of mAbs to CD8, CD4, NK1.1, or CD19, 1 day before and two days after tumor challenge, followed by injection of 250 μg every 5 days throughout the experiment. ...For the staining of immune cells, above prepared immune cells were washed with FACS staining buffer and incubated with mouse Fc receptor binding inhibitor (eBioscience) for 10 minutes before staining with mAbs (Tianjing Sungene) against mouse CD45 (clone 30-F11), CD3 (clone 145-2C11), CD4 (clone GK1.5), CD8 (clone 53–6.7), CD19 (clone eBio1D3), CD11b (clone M1/70) and Gr-1 (clone RB6-8C5) for 30 minutes. For intracellular staining of FoxP3 (clone FJK-16 s; eBioscience), cells were fixed, permeabilized and stained following the instruction of Cytofix/Cytoperm kit (BD Bioscience). ...The survival of mice was recorded. C and D, Mice (5/group) treated with combined anti-TIM-3/CD137 mAb were also injected with an anti-CD4, anti-CD8, anti-CD4/CD8, anti-NK1.1, anti-CD19, or control mAb with 250 μg of each mAb per mouse 1 day before and two days after tumor challenge and every 5 days thereafter for the duration of the experiments. ...We found that single TIM-3 blockade significantly increased the percentage of CD4+ T cells and slightly elevated the percentage of CD8+ T cells while it had little effects on the immunosuppressive CD4+FoxP3+ Treg, CD11b+GR-1+ MDSCs and CD19+ B cells in peritoneal lavage.
Tags: bioactivity of anti-mouse CD19 1D3 antibody; anti-mouse CD19 1D3 of low endotoxin

Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants.
Purtha, W. E., et al. J Exp Med. 2011 Dec 19;208(13):2599-606. doi: 10.1084/jem.20110740. PMID: 22162833
At different time points after WNV-WT infection, CD19+ B cells from the spleen were diluted serially, antibody secretion was induced (Amanna and Slifka, 2006), and supernatants were tested for reactivity to DIII or DIII-K307E/T330I. ...We adoptively transferred CD19+CCR6+CD80+IgM−IgD−lin− MBCs from vaccinated C57BL/6J-Igha mice into antibody allotype-mismatched Ighb C57BL/6 mice and challenged recipients with either WNV-WT or WNV-K307E. ...60 d after immunization with JEV-DIII, mice were administered CD20 or isotype control mAb. After 2 wk, the depletion of CD19+ B cells was confirmed by analysis of peripheral blood. ...Mice were rested for 13 wk to allow restoration of naive CD19+ B cells before challenge with WNV. ...CD19+CCR6+CD80+ class-switched IgM−IgD− cells were sorted into media (DME supplemented with 10% FBS, 10 mM Hepes, 10 mM nonessential amino acids, 10 mM sodium pyruvate, and penicillin and streptomycin) using a FACSAria II (BD).
Tags: anti-mouse CD19 1D3 antibody of low endotoxin; anti-mouse CD19 (1D3) in vivo antibody

B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging.
Keren, Z., et al. Blood. 2011 Mar 17;117(11):3104-12. doi: 10.1182/blood-2010-09-307983. PMID: 21228330
To deplete B cells in vivo, mice were injected intraperitoneally with the following mixture of monoclonal antibodies at 150 μg/mouse each: rat anti–mouse CD19 (clone 1D3), rat anti–mouse B220 (clone RA36B2), and mouse anti–mouse CD22 (clone CY34). ...The IgM versus AA4.1 plots were gated for CD19+/B220+ cells, and the B220 versus CD43 plots were gated on IgM− cells. (B) Absolute numbers of CD19+/B220+ cells in the BM of the indicated mice. ...A significant advantage of this depletion approach is the fact that most of the primary antibodies in this mixture (specific for CD19 and B220) are derived from rat and are rapidly cleared when injected into mice (within 5 days, supplemental Figure 2A). ...In each round, mice were first injected intraperitoneally (day 0) with a mixture of monoclonal antibodies specific to B220 (150 μg/mouse), CD19 (150 μg/mouse), and CD22 (150 μg/mouse), followed by a second intraperitoneal injection of rat anti-mouse κ monoclonal antibodies (150μg/mouse) 48 hours later (more details on the effectiveness and the specificity of the depletion is detailed shown in supplemental Figure 2). ...Spleen cells from the indicated mice were analyzed by flow cytometry. Analysis for B220 and PanCD45 was conducted on gated CD19+ cells. The plots shown are representative of 4 mice in each group.
Tags: clone 1D3 of anti-mouse CD19 antibody; mouse CD19 antibody (clone 1D3)

For more references about Anti-mouse CD19 Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following in vivo grade recombinant anti-mouse CD19 monoclonal antibodies:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3)

Syd Labs provides the following in vivo grade recombinant anti-human CD19 monoclonal antibodies:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1)
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43)
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63)

Syd Labs provides the following recombinant anti-mouse CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry

Syd Labs provides the following recombinant anti-human CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43) for flow cytometry